Microneedle based therapy

  • Research type

    Research Study

  • Full title

    Minimally invasive transfer of healthy cells for the treatment of vitiligo

  • IRAS ID

    186661

  • Contact name

    James C Birchall

  • Contact email

    birchalljc@cardiff.ac.uk

  • Sponsor organisation

    Cardiff University

  • Duration of Study in the UK

    1 years, 2 months, 0 days

  • Research summary

    The pigment in our skin is created by specialised pigment producing cells. Sometimes these cells do not work properly, causing loss of pigment in the skin. White patches appear in the affected areas. This condition is called vitiligo. Vitiligo affects approximately 1% of the population worldwide. A cure for vitiligo is not available to date, therefore the treatment options offered to patients are not always successful.

    Some vitiligo patients are eligible for a treatment called cellular grafting. This involves taking healthy pigment producing cells from an unaffected area of the patient’s skin that is not affected by vitiligo and transferring these cells to a white patch of skin. The aim is to replace the pigment producing cells.
    This technique is quite successful (pigmentation reappears in approximately 70% of patients). However, during this treatment the surface of the white skin must be removed in order to transplant the healthy cells. The process of removing the skin surface is called dermabrasion. Dermabrasion can be painful, can lead to scarring and area must be immobilised for up to 30 days after treatment.

    In this study we are testing a new method to transfer the healthy cells to the white skin. This will involve placing the healthy cells in the skin using tiny needles that are thinner than a human hair. These are called microneedles. Microneedles should cause minimal pain, no scarring and should reduce the risk of infection. We also hope there would be no need for immobilization after treatment.

    The purpose of this study is therefore to test if microneedles provide a patient-friendly and effective improvement for cellular grafting.

  • REC name

    Wales REC 2

  • REC reference

    16/WA/0086

  • Date of REC Opinion

    24 Mar 2016

  • REC opinion

    Further Information Favourable Opinion